MIST

Milestone is a newly-commercial biopharma whose entire equity story rests on one product: CARDAMYST (etripamil) nasal spray, FDA-approved on December 12, 2025 and only in retail pharmacies since Q1 2026. The MD&A frames a large opportunity — an estimated 2M+ Americans with PSVT, a target of 500,000–800,000 treatable patients in peak years and 2.5–4M episodes annually — but every FY2025 figure predates a single dollar of proven sales. Revenue is blank across FY2021–FY2025, so there is no commercial traction to underwrite; the addressable-market math is management projection, not results.

The fundamentals are those of a cash-burning pre-revenue company. FY2025 net loss widened to -$63.1M (YoY -51.9%) and operating cash flow was -$49.0M (YoY -70%, i.e. burn accelerated). Against that, cash of $73.0M implies roughly a year to eighteen months of runway before a commercial-launch ramp that typically raises spend — meaning another financing is a when, not an if. That risk is already visible in the capital structure: shares outstanding jumped +120.5% to 118M in a year, and the accumulated deficit sits at -$431M. Long-term debt of $57.2M and liabilities/equity of 1.72x add leverage on top of the dilution. ROE of -151% is arithmetic on a thin, deficit-riddled equity base.